Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products or revenue. Its pipeline centers on soquelitinib, an oral, selective inhibitor of ITK (interleukin-2 inducible T cell kinase), an enzyme that controls T cell activation and differentiation. By blocking ITK, soquelitinib suppresses pro-inflammatory immune pathways while preserving anti-tumor immunity — a profile that gives it potential in both cancer and autoimmune disease. Corvus is currently running a Phase 3 trial in relapsed peripheral T cell lymphoma (PTCL), a rare and aggressive blood cancer, where Phase 1 data showed a 26% complete response rate and median overall survival of 28 months in a selected patient subset. Corvus is also running a Phase 2 trial in moderate-to-severe atopic dermatitis, where Phase 1 data showed 75% of patients achieving EASI 75 at the 200mg twice-daily dose. Corvus's broader strategy mirrors the BTK inhibitor playbook — several Corvus founders, including CEO Richard Miller, helped develop ibrutinib, the first BTK inhibitor — with plans to expand soquelitinib into hidradenitis suppurativa, asthma, and solid tumors if early trials succeed. Corvus also has two earlier-stage candidates: ciforadenant, an adenosine receptor antagonist in a Phase 1b/2 renal cell carcinoma trial, and mupadolimab, an anti-CD73 antibody with development currently paused. Corvus funds operations entirely through equity financing, holds worldwide rights to soquelitinib except Greater China (licensed to Angel Pharmaceuticals), and relies on contract manufacturers.